世界の皮膚科市場見通し：2009〜2023年

原文目次

Abstract

This new market analysis by visiongain is to examine the current and future prospects for the world dermatological market. The world dermatological market generated total sales revenues of over $18bn in 2007. Visiongain predicts that this market area will expand further, increasing its total revenues significantly based on expansion of the market for modern drugs to treat skin disorders in developing countries, most notably China, India and Brazil. This report will outline the developments and explain their significance.

All the main dermatological market segments achieved positive sales growth from mid 2007 to mid 2008, giving hope for further gains. Dermatitis, anti-infectives and anti-acne treatments ranked as the top three therapeutic areas according to their sales performance. In this unique clear report, you will find out how those therapeutic areas and others fare from 2009 to 2023, as well as the performance of leading products there. This one-stop shop of information will deliver to you the performance of the current leading national markets for the products during that forecast period - will the US still dominate by such a large margin in 2013, 2018 and 2023?

This visiongain report - The World Dermatological Market Outlook, 2009-2023 - will specifically analyse the world markets for the following classes of dermatological treatments, with relevant sales forecasts:

• Dermatitis treatments
• Anti-infective agents
• Acne treatments
• Psoriasis treatments
• Miscellaneous dermatological agents.

The World Dermatological Market Outlook, 2009-2023 examines the market critically through a comprehensive review of available information. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. Sources used include industrial databases, commercial news, published reports and economic research. Importantly, visiongain applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market-centred report with detailed analysis and informed opinion.

In particular, The World Dermatological Market Outlook, 2009-2023 concentrates on the following essential aspects of that market:

• Forecast of the worldwide dermatological market from 2008-2023
• Forecasts of the leading market segments from 2008-2023
• Drivers and restraints facing the world dermatological market
• Opportunities and threats facing the world dermatological market
• Commercial prospects for the market-leading drugs, with global sales forecasts from 2008-2023
• Sales forecasts for the leading country markets from 2008-2023
• Analysis of pipeline developments in the sector
• Discussion of unmet therapeutic needs and relative advantages of products.

• To receive a comprehensive analysis of the prospects for dermatological drugs from 2008-2023
• To discover predicted revenues, growth rates and other key metrics for leading dermatological treatments from 2008-2023
• To discover "hot" pipeline developments and up-and-coming products
• To determine the forces that influence and characterise the market for dermatological treatments:
  • Competitive characteristics of the market
  • Drivers
  • Restraints
  • Strengths, weaknesses, opportunities and threats
• To find out where the market is heading - both technologically and commercially - from the present onwards.

The global dermatological treatments market has marked strengths and advantages, but is also limited by problems and concerns, like some other major pharma sectors. Growth of generics and biotechnological products create new opportunities. Clearly, that market sector will be driven by product launches and reformulations of existing drugs. Furthermore, the incidence of skin diseases is increasing, combined with an increased demand for treatments, especially in fast-developing nations. Visiongain believes that the global dermatological market has strong growth potential for both original branded and generic products. Market expansion will be heavily dependent on reformulations of existing products for improved drug delivery, new dosing schedules and targeting of specific patient populations. There are also promising dermatological agents currently in development; as discussed in this report, some of those potential market entrants have significant commercial potential. This report is essential reading for everybody involved in the dermatological treatments market, revealing prospects for both existing competitors and potential market entrants, from the present onwards.

Table of Contents

1. Executive Summary

• 1.1 Dermatological Market Review
• 1.2 Aims, Scope and Format of the Report

2. Introduction to Skin Diseases and Treatments

• 2.1 The Structure of the Skin
  • 2.1.1 Hair
  • 2.1.2 Sweat and Sebaceous Glands
  • 2.1.3 Nails
• 2.2 The Physiological Role of the Skin
  • 2.2.1 Protection
  • 2.2.2 Sensory Perception
  • 2.2.3 Storage
  • 2.2.4 Absorption/Vitamin D Formulation
  • 2.2.5 Temperature Regulation
• 2.3 Differences in Skin Due to Gender
• 2.4 The Effects of Age on Skin Structure
• 2.5 Inflammation and Histamine Release
• 2.6 Introduction to Dermatitis
  • 2.6.1 Atopic Dermatitis
  • 2.6.2 Contact Dermatitis
  • 2.6.3 Seborrheic Dermatitis
• 2.7 Introduction to Rosacea
  • 2.7.1 Symptoms
  • 2.7.2 Types and Causation
• 2.8 Introduction to Urticaria
  • 2.8.1 Acute Urticaria
  • 2.8.2 Chronic Urticaria
  • 2.8.3 Physical Urticaria
  • 2.8.4 Dermatographic Urticaria
• 2.9 Introduction to Alopecia
  • 2.9.1 Alopecia Areata
  • 2.9.2 Androgenic Alopecia
  • 2.9.3 Telogen Effluvium
  • 2.9.4 Trichotillomania and Traction Alopecia
• 2.10 Introduction to Skin Infection
  • 2.10.1 Bacterial Skin Infections
  • 2.10.2 Fungal Skin Infections
    • 2.10.2.1 Dermatophyte Infections
  • 2.10.3 Viral Infections
    • 2.10.3.1 Herpes Simplex
    • 2.10.3.2 Chicken Pox
    • 2.10.3.3 Herpes Zpster
    • 2.10.3.4 Warts
• 2.11 Introduction to Acne
  • 2.11.1 Pathogenesis
  • 2.11.2 Causation
  • 2.11.3 The Diagnosis of Acne
• 2.12 Introduction to Psoriasis
  • 2.12.1 Causation
  • 2.12.2 Symptoms
  • 2.12.3 Type
  • 2.12.4 Complications
• 2.13 Common Skin Treatments
  • 2.13.1 Creams and Semisolid Emulsions
  • 2.13.2 Ointments
  • 2.13.3 Lotions
  • 2.13.4 Solutions
  • 2.13.5 Occlusive Therapy
  • 2.13.6 Cleansing Agents
  • 2.13.7 Protectant Powders and Hydrophilic Polymers
  • 2.13.8 Anti-Infective Agents
  • 2.13.9 Anti-Inflammatory Agents

3. An Overview of the World Dermatological Market 2008-2023 (Including Forecasts in the Seven Major Markets)

• 3.1 The World Dermatological Market Analysis
  • 3.1.1 Strategic Analysis
• 3.2 The Leading Dermatological Markets: a Comparison
• 3.3 Medrol Currently Leads the World Dermatological Market - But Will it Last?
• 3.4 The Dermatitis Market Dominates the Dermatological Industry
• 3.5 Pharmaceutical Companies Accept that Dermatological Blockbuster Sales Will Be Difficult to Achieve
• 3.6 While the Past Has Been Difficult for Dermatological Treatments, There is Optimism for the Future
• 3.7 The Top 10 Companies in the Dermatological Market
• 3.8 The Dermatological Market, Regional Breakdown
• 3.9 Dermatological Sales in the Seven Major Markets
  • 3.9.1 Dermatological Market in the US
  • 3.9.2 Dermatological Market in Japan
  • 3.9.3 Dermatological Market in France
  • 3.9.4 Dermatological Market in Germany
  • 3.9.5 Dermatological Market in the UK
  • 3.9.6 Dermatological Market in Italy
  • 3.9.7 Dermatological Market in Spain

4. The World Dermatitis Market Analysis 2008-2023

• 4.1 Dermatitis Market Analysis - Overview
• 4.2 Medrol Currently Leads the Dermatitis and Dermatological Market
  • 4.2.1 Development of Medrol (methylprednisolone acetate)
• 4.3 Celestone Analysis
  • 4.3.1 Development of Celestone (betamethasone)
• 4.4 Elocon Suffers From Generic Competition
  • 4.4.1 Development of Elocon (mometasone fuorate)
• 4.5 Dermovate Will Increase in Revenues During 2008-2013 - But Will Growth Last Beyond that Period
  • 4.5.1 Development of Dermovate/Olux/Clob X (Clobetasol)
• 4.6 Kenacort A to Show an Early Increase in Revenues
  • 4.6.1 Kenacort A
• 4.7 The Dermatitis Market - Summary

5. The World Skin Infection Market Analysis 2008-2023

• 5.1 Skin Infection Market Analysis - Overview
• 5.2 Aldara Currently Leads the Skin Infection Market - But Will it Hold During the Forecast Period
  • 5.2.1 Development of Aldara (imiquimod)
• 5.3 Zovirax Will Show an Early Increase in Revenues
  • 5.3.1 Development of Zovirax (acyclovir)
• 5.4 Bactroban Will Decline in Revenues During the Forecast Period
  • 5.4.1 Development of Bactroban (mupirocin)
• 5.5 Lamisil Will be Affected by Patent Expiration
  • 5.5.1 Development of Lamisil (terbinafine)
• 5.6 Nizoral Will Suffer from Generic Competition
  • 5.6.1 Development of Nizoral (ketoconazole)
• 5.7 The Skin Infection Market - Summary

6 The World Acne Market Analysis 2008-2023

• 6.1 Acne Market Analysis - Overview
• 6.2 Differin Currently Leads the Acne Market
  • 6.2.1 Development of Differin (Adapalene)
• 6.3 Diane Open to Generic Competition
  • 6.3.1 Development of Diane (cyproterone/ethinylestradiol)
• 6.4 Benzaclin Will Exhibit Positive Growth - However Can it Withstand Pressure From its Main Rival?
  • 6.4.1 Benzoyl Peroxide and Clindamycin (Benzaclin and Duac)
• 6.5 Roaccutane Associated With Side Effects
  • 6.5.1 Development of Roaccutane (isotretinoin)
• 6.6 Duac Revenues During the Forecast Period
• 6.7 The Acne Market - Summary

7. The World Psoriasis Market Analysis 2008-2023

• 7.1 Psoriasis Market Analysis - Overview
• 7.2 Raptiva Currently Leads the Psoriasis Market
  • 7.2.1 Development of Raptiva (efalizumab)
• 7.3 Daivobet Growth During the Forecast Period
• 7.4 Dovonex Will Suffer From Strong Competition
• 7.5 Taclonex Sales Trends
  • 7.5.1 Dovonex/Daivobet/Taclonex (calciportiene/betamethasone)
• 7.6 Soriatane Sales Will Be Boosted by its Strong Efficacy in Psoriasis Treatment
  • 7.6.1 Soriatane (acitretin)
• 7.7 The Psoriasis Market - Summary

8. The World Market for Miscellaneous Dermatologicals 2008-2023

• 8.1 Miscellaneous Market Analysis
• 8.2 Proscar Sales Trends from 2008-2023
• 8.3 Will Surgicel Show Positive Sales Growth?
• 8.4 Betadine Shows Some Positive Growth - But Will it Continue?
• 8.5 The Miscellaneous Market - Summary

9. SWOT Analysis of the Dermatological Market

• 9.1 SWOT Analysis
• 9.2 Market Drivers
• 9.3 Market Restraints
• 9.4 There is Scope for Expansion into Related Markets
• 9.5 Advances in Technology Likely to Bring Benefits to the Market
• 9.6 Consumer Bargaining Power
• 9.7 Comparative Studies - a Two Edged Sword
• 9.8 Competition in the Dermatological Market to Become Increasingly Marked
• 9.9 Substitutes and Related Threats
• 9.10 A Discussion of Generic Drugs in This Market - How Great is Their Competitive Threat?

10. Pipeline Developments in the Dermatological Market

• 10.1 The Potential of the Dermatological Market Has Encouraged R&D
• 10.2 New Technology Leads to Interesting Pipeline Developments
• 10.3 Potential Entrants
• 10.4 Late-Stage Pipeline Products in the Dermatitis Sector
• 10.5 Late-Stage Pipeline Products in the Skin Infection Sector
• 10.6 Late-Stage Pipeline Products in the Acne Sector
• 10.7 Late-Stage Pipeline Products in the Psoriasis Sector
• 10.8 Late-Stage Pipeline Products in the Miscellaneous Sector
• 10.9 Innovation Rules for Early-Stage Pipeline Drugs

11. Conclusions

• 11.1 The Dermatological Market is Heading for Gradual Financial Growth
• 11.2 Market Drivers in the Dermatological Sector
• 11.3 Market Restraints in the Dermatological Sector
• 11.4 Medrol Currently Leads the World Dermatological Market
• 11.5 Will the Dermatitis Market Continue to Dominate?
• 11.6 The Skin Infection Market
• 11.7 The Acne Market
• 11.8 The Psoriasis Market
• 11.9 Why Growth in the Overall World Dermatological Market Will Continue

• Table 3.1 The World Dermatological Market Forecast ($m), 2008-2023
• Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for the Leading Dermatological Markets, 2007 & 2013
• Table 3.3 Top Ten Products in the Dermatological Market ($m), 2007
• Table 3.4 Top 10 Companies Revenues ($m) in the Dermatological Market, 2007
• Table 3.5 Dermatological Market Revenues ($m), Sales by Region 2007
• Table 3.6 Dermatological Market Forecast ($m) in the Seven Major Markets, 2008-2023
• Table 3.7 Dermatological Market Share (%) Comparison in the Seven Major Markets, 2007, 2010 & 2013
• Table 4.1 The World Dermatitis Market ($m) Forecast 2008-2023
• Table 4.2 Top 5 Products Rank Comparison, 2007 and 2023
• Table 5.1 The World Skin Infection Market ($m) Forecast 2008-2023
• Table 5.2 Top 5 Products Rank Comparison, 2007 and 2023
• Table 6.1 The World Acne Market ($m) Forecast 2008-2023
• Table 6.2 Top 5 Products Rank Comparison, 2007 and 2023
• Table 7.1 The World Psoriasis Market ($m) Forecast 2008-2023
• Table 7.2 Top 5 Leading Products Rank Comparison, 2007 and 2023
• Table 8.1 The World Miscellaneous Treatments Market ($m) Forecast, 2008-2023
• Table 9.1 SWOT Chart for the Dermatological Market, 2008-2023
• Table 10.1 Late-Stage Pipeline Drugs for Skin Infection, 2008
• Table 10.2 Late-Stage Pipeline Drugs for Acne, 2008
• Table 10.3 Late-Stage Pipeline Drugs for Psoriasis, 2008
• Table 10.4 Late-Stage Pipeline Drugs for Miscellaneous Disorders, 2008
• Table 11.1 Leading Dermatological Markets Revenue Forecasts ($m), 2008-2023

• Figure 3.1 The Leading Dermatological Markets Revenue ($m), 2008-2023
• Figure 3.2 Leading Dermatological Markets Revenue ($m) Comparison, 2007 & 2013
• Figure 3.3 Leading Dermatological Sectors Market Share (%), 2007
• Figure 3.4 Leading Dermatological Sectors Market Share (%), 2013
• Figure 3.5 Top Ten Products Revenue ($m) in the Dermatological Market, 2007*
• Figure 3.6 Market Share (%) of Top Ten Dermatological Products, 2007
• Figure 3.7 Market Share (%) of the Top 10 Companies, 2007
• Figure 3.8 Market Share (%) of the Dermatological Market by Region, 2007
• Figure 3.9 Dermatological Market Revenue ($m) in the Seven Major Markets, 2007*
• Figure 3.10 Dermatological Market Share (%) in the Seven Major Markets, 2007
• Figure 3.11 Dermatological Market Share (%) in the Seven Major Markets, 2010
• Figure 3.12 Dermatological Market Share (%) in the Seven Major Markets, 2013
• Figure 4.1 Market Share (%) of Leading Dermatitis Products, 2007
• Figure 4.2 Market Share (%) of Leading Dermatitis Products, 2010
• Figure 4.3 Market Share (%) of Leading Dermatitis Products, 2013
• Figure 4.4 Dermatitis Market Revenue Forecast ($m), 2008-2023
• Figure 4.5 Medrol Revenue Forecast ($m), 2008-2023
• Figure 4.6 Celestone Revenue Forecast ($m), 2008-2023
• Figure 4.7 Elocon Revenue Forecast ($m), 2008-2023
• Figure 4.8 Dermovate Revenue Forecast ($m), 2008-2023
• Figure 4.9 Kenacort A Revenue Forecast ($m), 2008-2023
• Figure 5.1 Market Share (%) of the Leading Skin Infection Products, 2007
• Figure 5.2 Market Share (%) of the Leading Skin Infection Products, 2010
• Figure 5.3 Market Share (%) of the Leading Skin Infection Products, 2013
• Figure 5.4 Skin Infection Market Revenue Forecast ($m), 2008-2023
• Figure 5.5 Aldara Revenue Forecast ($m), 2008-2023
• Figure 5.6 Zovirax Revenue Forecast ($m), 2008-2023
• Figure 5.7 Bactroban Revenue Forecast ($m), 2008-2023
• Figure 5.8 Lamisil Revenue Forecast ($m), 2008-2023
• Figure 5.9 Nizoral Revenue Forecast ($m), 2008-2023
• Figure 6.1 Market Share (%) of the Leading Acne Products, 2007
• Figure 6.2 Market Share (%) of the Leading Acne Products, 2010
• Figure 6.3 Market Share (%) of the Leading Acne Products, 2013
• Figure 6.4 Acne Market Revenue Forecast ($m), 2008-2023
• Figure 6.5 Differin Revenue Forecast ($m), 2008-2023
• Figure 6.6 Diane Revenue Forecast ($m), 2008-2023
• Figure 6.7 Benzaclin Revenue Forecast ($m), 2008-2023
• Figure 6.8 Roaccutane Revenue Forecast ($m), 2008-2023
• Figure 6.9 Duac Revenue Forecast ($m), 2008-2023
• Figure 7.1 Market Share (%) of the Leading Psoriasis Products, 2007
• Figure 7.2 Market Share (%) of the Leading Psoriasis Products, 2010
• Figure 7.3 Market Share (%) of the Leading Psoriasis Products, 2013
• Figure 7.4 Psoriasis Market Revenue Forecast ($m), 2008-2023
• Figure 7.5 Raptiva Revenue Forecast ($m), 2008-2023
• Figure 7.6 Daivobet Revenue Forecast ($m), 2008-2023
• Figure 7.7 Dovonex Revenue Forecast ($m), 2008-2023
• Figure 7.8 Taclonex Revenue Forecast ($m), 2008-2023
• Figure 7.9 Soriatane Revenue Forecast ($m), 2008-2023
• Figure 8.1 Market Share (%) of the Leading Miscellaneous Products, 2007
• Figure 8.2 Market Share (%) of the Leading Miscellaneous Products, 2010
• Figure 8.3 Market Share (%) of the Leading Miscellaneous Products, 2013
• Figure 8.4 Miscellaneous Market Revenue Forecast ($m), 2008-2023
• Figure 8.5 Proscar Revenue Forecast ($m), 2008-2023
• Figure 8.6 Surgicel Revenue Forecast ($m), 2008-2023
• Figure 8.7 Betadine Revenue Forecast ($m), 2008-2023

Companies Listed

• Abbott
• Aegis
• Allergan
• Almirall
• Altana
• Astellas
• Bayer
• Bayer Schering
• Berlex
• Biogen Idec
• Boryung
• Cellegy
• Centocor
• Cipher
• Clinuvel
• Dr. Reddy' s Laboratories
• EpiCept
• Galderma
• Genaera
• GlaxoSmithKline
• Gruenenthal
• Isotechnika
• Johnson & Johnson
• LEO Pharma
• L' Oreal
• Lupin
• Manhattan
• Meda
• Medivir
• Merck &Co
• Migenix
• Minnesota 3M
• Moberg Derma
• Mylan
• Nestle (Alcon)
• NexMed
• Novartis
• Nycomed Pharma
• Peplin
• Pfizer
• Procept
• QLT
• Roche
• Sanofi-Aventis
• Schering-Plough
• Shionogi
• Stiefel
• Taro Pharmaceuticals
• Teva
• Tolerx
• Wyeth

関連商品

処方薬関連調査レポート

オピオイドの処方にみられる傾向 - 効能面の優位性で画期的な疼痛管理の主力薬であり続けるオピオイド

Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management

価格: ￥281,645 (税抜) より

出版日: 2012年05月

抗高血圧薬市場（〜2017年）：ブロックバスター薬（Diovan、Micardis、Avapro、Atacandなど）の特許失効が目減りを加速

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

価格: ￥281,645 (税抜) より

出版日: 2012年03月

世界の皮膚科処方薬市場：第8版（抗ニキビ、アンチエイジング、皮膚炎、抜け毛、乾癬、皮膚癌、肝斑、および脂漏症の治療）

World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)

価格: ￥321,477 (税抜) より

出版日: 2012年03月

ビジョンゲイン発行の医薬品関連調査レポート

医薬品有力企業シリーズ：ジェネリック薬メーカー上位50社 2012-2022年

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

価格: ￥212,601 (税抜) より

出版日: 2012年03月

眼科用医薬品の世界市場の見通し

Ophthalmic Drugs: World Market Prospects 2012-2022

価格: ￥212,601 (税抜) より

出版日: 2012年03月

主要抗癌剤および関連市場：2012-2022年

Leading Anti-Cancer Drugs and Associated Market 2012-2022

価格: ￥212,601 (税抜) より

出版日: 2012年02月

無料メールサービス

各カテゴリの最新刊情報やキャンペーン情報をメールにてご案内するサービスです。